- Caliper Addresses Key Bottlenecks in Quality by Design Initiative for Protein Therapeutics -
HOPKINTON, Mass., June 29 Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today launched the Staccato Protein Workstation to specifically address bottlenecks in the characterization of biological therapeutics and biogenerics.
With a goal of assuring the quality of therapeutic proteins and monoclonal antibodies, as well as creating mechanisms for approval of follow-on protein products (biosimilars), the FDA has encouraged the industry to submit biological new drug applications that include quality by design (QbD) parameters. QbD approaches require multivariate experimentation techniques that generate large numbers of samples and create bottlenecks in sample preparation and analysis.
"The Staccato Protein Workstation is designed to address the sample preparation and analysis bottlenecks caused by increased sample requirements of QbD approaches, and is also directly applicable to research groups performing protein expression optimization, clone selection, and other high throughput techniques," said Kevin Keras, Business Unit Manager, ACES, Caliper Life Sciences. "Caliper has worked with several of our LabChip GXII customers, including Dow and Amgen, to develop custom automation solutions to integrate sample preparation and analysis steps. Recognizing the broader need for this workflow automation, Caliper has created the Staccato Protein Workstation as an off-the-shelf solution."
The Staccato Protein Workstation, developed by Caliper's Automation, Consulting, Engineering, and Services (ACES) group, incorporates the Sciclone ALH 3000 for automated liquid handling, Twister II for microplate handling, LabChip GXII for microflui
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved